Effect of Lansoprazole on Kidney Volume and GFR by Iohexol in Thai ADPKD Patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210208005

Enrollment

Registered

2021-02-08

Start date

2020-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total kidney volume progression and GFR declined in ADPKD patients ADPKD Total kidney volume GFR decline Lansoprazole

Interventions

lansoprazole (30mg ) 2 tab po bid ac,placebo (30mg) 2 tab po bid ac

Active Comparator Drug,Placebo Comparator Drug

lansoprazole,placebo

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. ADPKD diagnosed by Revine criteria, 2. eGFR by CKD-EPI at least 30 mL per min per 1.73 m2, 3. Total kidney volume by MRI at least 1000 mL, 4. Informed consent

Exclusion criteria

Exclusion criteria: 1. Renal transplantation, 2. Contraindicate to MRI, 3. pregnancy or breast feeding, 4. Critical illness or short life expectancy, 5. No informed consent or desire to withdraw from the study

Design outcomes

Primary

Measure	Time frame
total kidney volume 12 months MRI kidney	—

Secondary

Measure	Time frame
Glomerular filtration rate 12 months blood sampling	—

Countries

Thailand

Contacts

Public ContactChalothorn Taesilpasathit

investigator

chalothorn.n@gmail.com0898961008

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026